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ABSTRACT
Background: Accurate prediction of a patient’s prognosis is useful to define the risk posed by the disease. Age, gender, peripheral blood cyto-
penia, proportion of bone marrow (BM) blasts, performance status, comorbidities, transfusion dependence, specific karyotype abnormalities 
and molecular biomarkers can refine the prediction of prognosis in MDS. Aim: to assess the influence of the some prognostic factors like age, 
gender, cytopenia, BM blast percentage, transfusion dependence, ferritin, hemoglobin (Hb), lactate dehydrogenase (LDH), albumin and specific 
karyotype abnormalities in myelodysplastic syndromes on overall survival (OS). Patients and methods: we retrospectively analyzed the cohort 
of 108 patients diagnosed between 1.1.2011 and 31.12.2013 at the University Clinic of Hematology, Ss Cyril and Methodius University, Skopje, 
Macedonia. They were evaluated for clinical and hematologic features at diagnosis and at leukemic transformation. Results: in the study group 
62 were man and 46 women. Male to female ratio was 1.35 to 1. The differences in OS between men and women were significant (p = .03015). 
The mean age at diagnosis was 66,6 years. According to the age OS was 16,4 months. FAB subtypes influenced OS significantly (p = .03015). OS 
inversely correlated with BM blast percentage (p= .02327). Cytopenia had no impact on OS (p=.33755). Hb as a whole and groups with different 
levels of Hb had no influence on OS (p = .12142) and (p= .07535), respectively. The group with ferritin <500 µg/L had better OS (p=.04720). 
Transfusion dependence, LDH and albumin had no impact on OS. Leukemic transformation was noticed in 10 (9,3%) patients. Mortality was 
36,1%. Conclusion: gender, FAB subtypes, BM blast percentage and the serum levels of ferritin had an influence on OS, while age, hemoglobin 
level, transfusion dependence, LDH and albumin had no impact on OS.
Key words: myelodysplastic syndromes, prognostic factors, overall survival.
1. INTRODUCTION
Myelodysplastic syndromes (MDSs) are a heterogeneous
group of disorders characterized by dysplasia in one or more cell 
lines, followed by a progressive impairment in the ability to dif-
ferentiate, manifested with peripheral cytopenia and an increas-
ing risk of evolution into acute myeloid leukemia (AML) (1, 2).
The clinical course is variable so much effort has been focused 
on methods for predicting prognosis. Accurately predicting the 
prognosis once a malignancy has been diagnosed is of great im-
portance to both patients and their physicians alike (1). From 
a patient’s perspective, the prognosis helps define the severity 
of disease and sets expectations as to how it is likely to impact 
them. In contrast, prognostic information from a physician’s 
standpoint is essentially a means of staging the disease in a man-
ner that can be used to help direct therapy (3). For both patients 
and physicians, the estimation of prognosis is a continual process 
that does not happen just at the time of diagnosis. Reevaluat-
ing the prognosis may be useful when a patient shows signs of 
progression or after they have become refractory to standard 
treatment (3). The vast majority of cases (80% to 90%) occur ‘de 
novo’, whereas 10% to 20% of cases are secondary (4). French-
American British (FAB) classification for MDS is still in use, 
based on morphologic findings (5). The standard prognostic tool 
for prognosis in MDS is the International Prognostic Scoring 
System (IPSS) which classifies patients into low-, intermedi-
ate-1, intermediate-2 and high-risk categories. IPSS takes into 
account BM blast percentage, number of cytopenia and cytoge-
netic abnormalities (6, 7, 8). Beside the known prognosis factors 
included in the IPSS, other variables that have an impact on 
prognosis in MDS were studied: age (4, 9, 10, 11, 12), gender (4, 
11, 12), FAB subtypes (13), degree of anemia and RBC transfu-
sion dependence (7, 8), ferritin (14, 15, 16, 17, 18), LDH (19), 
albumins (20), mutations (21, 22, 23) and comorbidities (24).
Diagnosis requires BM examination and cytogenetic studies, 
and lately molecular studies. The consensual minimum criterion 
for diagnosis is the presence of erythroid, granulocyte or mega-
karyocyte dysplasia in 10% or more of informative cells (25). 
One must exclude the possibility of erythroid dysplasia associ-
ated with vitamin B12/ folate/copper deficiency, viral infections, 
chemotherapy, or lead/arsenic poisoning (26).
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The incidence of MDS increases with age (median about 70 years). 
MDS is rare in children (4, 9, 10, 11, 36) Age had a significant 
effect on OS of the MDS population analyzed as a whole and 
stratified by subgroups–the older the age, the worse the progno-
sis. During the analysis on the subgroups, the effect of age was 
statistically relevant within RA and RARS patients, whereas it 
was not significant within and RAEB subgroup (36).
A significant influence of sex on OS was observed in several 
studies. The overall incidence of MDS is slightly higher in males 
than in females (1.5–2 to 1). Male patients had worse prognosis 
(4, 11). Considering subgroups, the effect of sex was relevant in 
refractory cytopenia, but did not affect the outcome in patients 
with RAEB (36).
According to the multivariate analysis peripheral cytopenia 
did not reach a statistical significance on OS in MDS patients 
(12). FAB subtypes can worsen the prognosis in MDS in terms 
of OS, with differences among subtypes. Refractory anemia had 
the best and RAEB-T the worst prognosis (13).
Blast count showed a significant predictive value on OS in 
MDS patients (36). More than 5% blasts in BM are considered 
as a bad prognostic factor for OS and leukemic transformation 
(23, 27).
Red blood cell (RBC) transfusions are a commonly used ther-
apy to treat symptomatic anemia that affects most patients with 
MDS. Transfusion dependence is defined by the MDS Interna-
tional Study Group (2000) as requiring transfusion of at least 
one RBC at 8 weeks for 4 months (13). Transfusion-dependent 
patients had shorter survival rate than those who received less 
than 18 units of blood over a period of 36 months (37).
Serum ferritin level ≥500 µg/l at diagnosis was a strong inde-
pendent predictor of survival. Serum ferritin was significantly 
correlated with OS in Chinese patients (14). These patients 
suffer from comorbidities such as heart failure, diabetes, infec-
tions, disorders of the thyroid gland and liver, shortening their 
survival (14, 15, 16, 17, 18).
Lactate dehydrogenase (LDH) is a parameter that should be 
recognized as a prognostic factor in MDS (19). One German 
study pointed out the correlation between LDH level and OS 
(23). Serum albumin is an independent prognostic factor that 
influences OS in patients with MDS. Hypoalbuminemia is a 
marker for shorter OS in MDS (20).
Recurrent chromosomal abnormalities have been identified 
in 40–70% of the ‘de novo’ MDS and 95% of secondary MDS. 
These chromosomal aberrations include 5q-, 7q-/-7, +8, 20q-, 
12p-, abnormalities in 17p, 11q23 and chromosome 3 (28). 
Favorable prognostic markers according to IPSS include: a nor-
mal karyotype, 5q- as an isolated anomaly, 20q- as an isolated 
anomaly and -Y chromosome. Karyotype findings associated 
with poor prognosis include complex karyotype and abnormali-
ties of chromosome 7. Other cytogenetic abnormalities confer 
an interme diate prognosis (1, 28). Abnormal karyotype corre-
lates with poor prognosis and shorter OS (21, 29). According 
to the multivariate analysis, cytogenetics showed a significant 
predictive value on OS (12).
Somatic mutations are identified in more than 70% of pa-
tients with MDS, including more of the patients with normal 
karyotype. These mutations are major predictors of the clinical 
phenotype, and could also be predictors of prognosis (21, 22, 23).
The incidence of MDS increases with the age, so does the 
prevalence of comorbidities. About 50% of MDS patients have 
one or more comorbidities. Congestive heart disease, hyperten-
sion, lung diseases, diabetes, liver failure, bleeding and solid tu-
mors are cited as the most often reasons for non-leukemic dead 
(24). Comorbidities are significant and independent predictors 
in MDS (24). Congestive heart disease and chronic obstructive 
lung disease are associated with shorter OS, while diabetes and 
cerebro-vascular diseases do not change prognosis in MDS (24).
The median OS in MDS is 2.5 years (10). Prognosis is poor 
for patients with MDS, with 3-year survival rates estimated at 
less than 50% (30). The median survival rates according to IPSS 
are estimated at 8, 5.3, 2.2, and 0.9 years, respectfully (23, 31).
2. AIM
The aim of this study was to assess the influence of the some 
prognostic factors in myelodysplastic syndromes (age, gender, 
cytopenia, BM blast percentage, transfusion dependence, serum 
levels of hemoglobin, ferritin, lactate dehydrogenase and albu-
min, and specific karyotype abnormalities) on OS.
3. PATIENTS AND METHODS
We retrospectively analyzed the cohort of 108 patients 
(62 male and 46 female) diagnosed between 1.1.2011 and 
31.12.2013 at the University Clinic of Hematology, Ss Cyril and 
Methodius University, Skopje, Macedonia. They were evaluated 
for clinical and hematologic features at diagnosis and leukemic 
transformation. Observation time was 36 months. Diagnosis 
was made upon dysplastic changes in peripheral blood smear 
and bone marrow aspirate. Confirmation analysis included bone 
marrow aspirate, cytochemical stain, immunohistochemical 
tests, cytochemical stain of medullar iron and karyotype analysis 
in some cases. We evaluated some parameters that could influ-
ence OS: age, gender, cytopenia, BM blast percentage, transfu-
sion dependence, serum levels of Hb, ferritin, LDH and albu-
min as well as specific karyotype abnormalities. Chromosomal 
analysis was performed only in 5 patients using BM aspirate, 
according to laboratory procedures. IPSS was not calculated 
in the vast majority of patients, because we could not perform 
cytogenetic analysis in all patients. Most patients (pts) received 
supportive care: transfusion of RBC and platelets, red cell and 
granulocyte growth factors (21 pts), vitamins, corticosteroids, 
iron chelatation therapy (7 pts), some received chemotherapy 
(4pts) and few patients allogeneic transplantation (3 pts). OS 
was estimated in months including the period from the date 
of diagnosis to the time of death / time of last visit. Leukemic 
transformation was noticed in 10 (9,3%) patients. Mortality 
was 36,1%. Infectious and hemorrhagic complications as well 
as BM failure were considered causes of MDS-related deaths.
4. RESULTS 
Mean age at diagnosis was 66,6 years (range 18-89) (SD 14.2). 
Mean OS depending on age was 16,4 months, and it was not 
statistically significant (p= .46375). In our study, 62 (57.4%) 
patients were men, 46 (42.6%) women. Male to female ratio was 
1.35 to 1. Women had better OS than men (p = .00819). (Fig-
ure 1). According to the FAB classification patients were clas-
sified as follows: 75 patients as having refractory anemia (RA; 
69.4%), 1–RA with ringed sideroblasts (RARS; 0.9%), 21–RA 
with excess of blasts (RAEB; 19.4%), 3–RAEB in transforma-
tion (RAEB-T 2.8%), and 8 as having chronic myelomonocytic 
leukemia (CMML 8.2%). (Table 1)
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FAB classification Number %
RA 75 69.4
RARS 1 0.9
RAEB 21 19.4
RAEB—Т 3 2.8
CMML 8 8.2
Table 1. Distribution of patients according to the FAB classification
Statistically significant differences in OS were found among 
patients with RA, RAEB, RAEB-T and CMML (p = .03015). 
(Figure 2)
Cytopenia had no influence on OS (p=.09340). In our group 
23 patients (21.3%) presented with one cytopenia, 46 patients 
(42.6) with bicytopenia and 39 patients (36.1%) with pancy-
topenia. There was no statistically significant difference in OS 
among patients with different cytopenia (p = .33755).
Percentage of BM blasts correlated with OS (p=.02327). 
Mean OS in the group with < 5% blasts was 17,8 months, in the 
group with blasts 5-9%–17.7 months, with blasts 10-19%–9.7 
months and in the group with 20-30% blasts – 9.5 months. The 
differences among groups were statistically significant (p<0.05).
Mean Hb level in our cohort was 85,1 g/L (range 41-150). Hb 
had no impact on OS (16.4 months) (p=.12142). The patients 
were grouped in three categories according to the severity of 
anemia: severe anemia (Hb <70 g/L), moderate anemia (Hb 
70-100 g/L) and patients with Hb >100 g/L. OS was highest 
in patients with Hb >100 g/L–21.6 months, in moderate ane-
mia–14,8 months and in severe anemia–15.2 months, being not 
statistically significant (p=0.07535).
Mean level of serum ferritin in our group was 3826.1µg/L. 
Serum ferritin had no impact on OS – 16,5 months (p=.13178). 
But, groups with ferritin <500 µg/L (17 months) and >500 µg 
/L (16 months) had significant differences in OS (p= .04720). 
(Figure 3).
Transfusion dependence is defined by the MDS International 
Group (2000) study as requiring transfusion of at least one 
packed red blood cells (RBC) at 8 weeks for 4 months (13) OS 
depending on transfusion as a whole was 16.2 months, being not 
statistically significant (p= .16298). OS in the group without 
RBC was 16.5 months, in the group that received ≤ 18 RBC had 
OS 15.4 months, and the group that received >18 RBC had OS 
19.8 months. Mean transfused doses in this cohort were 13.2 
RBC (St.dev.-16.8). Transfusion dependent patients with >18 
doses RBC had shorter survival than patients who required ≤ 
18 doses RBC, being not statistically significant (p=.72185).
Mean serum level of LDH was 809 IU/L. There was no sta-
tistical significance in OS between the two groups with different 
LDH (<423 IU/L and >423 IU/L) (p = .48310).
Mean albumin level in the study group was 39g/L. Albumins 
had no influence on OS – 20 months (p= .25087). There was 
no statistical significance in OS between the two groups with 
different levels of albumins (<40 g/L and >40 g/L) (p= .18986).
When testing mutual influence of several parameters on OS, 
we found that age, gender, FAB subtypes, bone marrow blast 
percentage, hemoglobin level and transfusion dependence had 
statistically significant impact on OS (p=.01628).
We were unable to perform cytogenetic analysis in all pa-
tients. From those 5 patients who underwent cytogenetic tests, 
3 had normal karyotype, one patient had +8 and one inv16. 
We could not show survival curves due to the small number of 
patients in whom cytogenetic analysis was performed.
5. STATISTICAL ANALYSIS
The statistical analysis was performed using statistical pack-
age SSPS 16.0. For the parameters or variables used in this paper, 
the range, mean and standard deviation were presented. Differ-
ences among variables were evaluated by the Chi-square test. The 
determinations of correlations between different variables was 
based on the Pearson correlation coefficient in all cases where 
the variables had a normal distribution, and a certain correla-
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Figure 2. OS depending on FAB subtypes 
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Figure 3. OS in groups with different serum ferritin levels 
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tion was considered statistically significant if p <0.05. Overall 
survival was defined as the time interval between diagnosis date 
and death date. Patients who were alive were censored at the last 
follow-up date. The probabilities of OS were estimated using 
the method of Kaplan and Meier. Cox proportional hazards 
regression models were used to assess the association between 
prognostic factors and OS.
6. DISCUSSION
Our results considering age (66.6 years) correspond with 
those in the literature (12). Age in this group did not affect 
OS neither as a whole nor stratified by subgroups, similar with 
some studies (36). Considering gender, men had worse OS than 
women, corresponding with the data in the literature (4, 11, 
32). FAB subtypes had a significant effect on OS. Considering 
subtypes, the worst results were observed in RAEB-T, than in 
CMML, RAEB and RA subtype, similar with those in the 
literature (13). There was only one patient with RARS and he 
was not taken in consideration. Cytopenia had no impact on 
OS, corresponding with some data in the literature (12). But, 
others showed opposite results (8, 27, 33, 34). OS correlated 
inversely with BM blast percentage, showed in other studies 
(23, 27). Hemoglobin as a whole and stratified into subgroups 
did not show any impact on OS (12). Transfusion dependence 
could be an independent prognostic factor for bad prognosis (2, 
17, 35), although in our study group the influence on OS was 
not significant. Serum ferritin level ≥500 µg/L at presentation 
is an independent poor predictor for OS (14). The group with 
ferritin <500 µg/L had better OS. LDH is a factor sited as 
having predictive value (19), although we could not prove that. 
Hypoalbuminemia is an independent poor prognostic factor in 
MDS patients (20), but in our study group it was not significant.
Cytogenetics in other studies showed a significant predic-
tive value on OS (36) and patients were accordingly stratified 
in groups with different IPSS score (3, 27, 29). Only 5 patients 
were analyzed for cytogenetic abnormalities, three of them with 
good prognosis, and two of them (+8, inv16) with intermedi-
ate prognosis.
Limitations in our study include retrospective analysis, insuf-
ficient data on cytogenetic analysis and impossibility to stratify 
patients according to IPSS score, lack of data on comorbidities, 
insufficient data on ferritin, LDH and albumins, that probably 
reflected on the results making some of them different than 
those cited in the literature.
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